Kyverna Therapeutics (NASDAQ:KYTX) Upgraded at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Kyverna Therapeutics (NASDAQ:KYTX – Free Report) from a sell rating to a hold rating in a research note issued to investors on Saturday.

KYTX has been the subject of a number of other research reports. Morgan Stanley set a $33.00 target price on shares of Kyverna Therapeutics in a research report on Monday, December 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Monday, December 29th. Finally, Wells Fargo & Company upped their target price on Kyverna Therapeutics from $31.00 to $33.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $28.67.

View Our Latest Analysis on Kyverna Therapeutics

Kyverna Therapeutics Price Performance

NASDAQ KYTX opened at $8.51 on Friday. The firm has a market capitalization of $372.74 million, a price-to-earnings ratio of -2.28 and a beta of 3.31. The company has a 50 day simple moving average of $8.44 and a 200-day simple moving average of $7.00. Kyverna Therapeutics has a 52-week low of $1.78 and a 52-week high of $13.67.

Insider Transactions at Kyverna Therapeutics

In other news, CTO Karen Marie Walker sold 23,998 shares of the company’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $12.20, for a total transaction of $292,775.60. Following the completion of the sale, the chief technology officer owned 22,636 shares in the company, valued at approximately $276,159.20. This represents a 51.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Biopartners Opportuni Westlake acquired 133,333 shares of the stock in a transaction dated Thursday, December 18th. The shares were bought at an average cost of $7.50 per share, for a total transaction of $999,997.50. Following the acquisition, the insider owned 869,317 shares in the company, valued at $6,519,877.50. The trade was a 18.12% increase in their position. The disclosure for this purchase is available in the SEC filing.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of KYTX. Public Employees Retirement System of Ohio bought a new position in Kyverna Therapeutics in the 3rd quarter worth $28,000. Phoenix Wealth Advisors acquired a new stake in shares of Kyverna Therapeutics in the second quarter valued at about $32,000. Catalyst Funds Management Pty Ltd bought a new position in shares of Kyverna Therapeutics in the second quarter worth about $37,000. Qube Research & Technologies Ltd bought a new position in shares of Kyverna Therapeutics in the second quarter worth about $43,000. Finally, Ethic Inc. acquired a new position in shares of Kyverna Therapeutics during the 2nd quarter worth about $56,000. 18.08% of the stock is currently owned by institutional investors and hedge funds.

Kyverna Therapeutics Company Profile

(Get Free Report)

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.

Further Reading